Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.

King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA.

Eur Radiol. 2012 Dec;22(12):2641-7. doi: 10.1007/s00330-012-2553-8. Epub 2012 Jul 4.

PMID:
22752463
2.

Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.

King V, Goldfarb SB, Brooks JD, Sung JS, Nulsen BF, Jozefara JE, Pike MC, Dickler MN, Morris EA.

Radiology. 2012 Sep;264(3):670-8. doi: 10.1148/radiol.12112669. Epub 2012 Jul 6.

PMID:
22771878
3.

The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.

Price ER, Brooks JD, Watson EJ, Brennan SB, Comen EA, Morris EA.

Eur Radiol. 2014 Jan;24(1):162-8. doi: 10.1007/s00330-013-2993-9. Epub 2013 Aug 28.

PMID:
23982290
4.

Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.

King V, Kaplan J, Pike MC, Liberman L, David Dershaw D, Lee CH, Brooks JD, Morris EA.

Breast J. 2012 Nov-Dec;18(6):527-34. doi: 10.1111/tbj.12002. Epub 2012 Sep 25.

PMID:
23002953
5.

Background parenchymal enhancement at breast MR imaging and breast cancer risk.

King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA.

Radiology. 2011 Jul;260(1):50-60. doi: 10.1148/radiol.11102156. Epub 2011 Apr 14.

PMID:
21493794
6.

Mammographic density, MRI background parenchymal enhancement and breast cancer risk.

Pike MC, Pearce CL.

Ann Oncol. 2013 Nov;24 Suppl 8:viii37-viii41. doi: 10.1093/annonc/mdt310.

7.

Impact of fibroglandular tissue and background parenchymal enhancement on diffusion weighted imaging of breast lesions.

Iacconi C, Thakur SB, Dershaw DD, Brooks J, Fry CW, Morris EA.

Eur J Radiol. 2014 Dec;83(12):2137-43.

PMID:
25445896
8.

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Chen JH, Yu H, Lin M, Mehta RS, Su MY.

Magn Reson Imaging. 2013 Nov;31(9):1465-71. doi: 10.1016/j.mri.2013.07.014. Epub 2013 Aug 29.

9.

Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.

Wu S, Weinstein SP, DeLeo MJ 3rd, Conant EF, Chen J, Domchek SM, Kontos D.

Breast Cancer Res. 2015 May 19;17:67. doi: 10.1186/s13058-015-0577-0. Erratum in: Breast Cancer Res. 2015;17:144.

10.

Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.

Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA.

AJR Am J Roentgenol. 2011 Jan;196(1):218-24. doi: 10.2214/AJR.10.4550.

PMID:
21178070
11.

Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training.

Melsaether A, McDermott M, Gupta D, Pysarenko K, Shaylor SD, Moy L.

AJR Am J Roentgenol. 2014 Jul;203(1):209-15. doi: 10.2214/AJR.13.10952.

PMID:
24951217
12.

Quantitative Assessment of Breast Parenchymal Uptake in 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.

Leithner D, Baltzer P, Magometschnigg H, Wengert G, Karanikas G, Helbich T, Weber M, Wadsak W, Pinker K.

J Nucl Med. 2016 May 26. pii: jnumed.116.174904. [Epub ahead of print]

PMID:
27230924
13.

Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?

Dontchos BN, Rahbar H, Partridge SC, Korde LA, Lam DL, Scheel JR, Peacock S, Lehman CD.

Radiology. 2015 Aug;276(2):371-80. doi: 10.1148/radiol.2015142304. Epub 2015 May 12.

PMID:
25965809
14.

Comparison of contrast enhancement and diffusion-weighted magnetic resonance imaging in healthy and cancerous breast tissue.

Cho GY, Moy L, Kim SG, Klautau Leite AP, Baete SH, Babb JS, Sodickson DK, Sigmund EE.

Eur J Radiol. 2015 Oct;84(10):1888-93. doi: 10.1016/j.ejrad.2015.06.023. Epub 2015 Jul 2.

PMID:
26220915
15.

Background 99mTc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imaging.

Yoon HJ, Kim Y, Lee JE, Kim BS.

Eur Radiol. 2015 Jan;25(1):32-40. doi: 10.1007/s00330-014-3400-x. Epub 2014 Sep 13.

PMID:
25216768
16.

Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy.

Hegenscheid K, Schmidt CO, Seipel R, Laqua R, Ohlinger R, Hosten N, Puls R.

Eur Radiol. 2012 Dec;22(12):2633-40. doi: 10.1007/s00330-012-2544-9. Epub 2012 Jul 8.

PMID:
22772146
18.

The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancer.

Albert M, Schnabel F, Chun J, Schwartz S, Lee J, Klautau Leite AP, Moy L.

Clin Imaging. 2015 Nov-Dec;39(6):987-92. doi: 10.1016/j.clinimag.2015.08.001. Epub 2015 Aug 6.

19.

Prediction of background parenchymal enhancement on breast MRI using mammography, ultrasonography, and diffusion-weighted imaging.

Kawamura A, Satake H, Ishigaki S, Ikeda M, Kimura R, Shimamoto K, Naganawa S.

Nagoya J Med Sci. 2015 Aug;77(3):425-37.

20.

Background parenchymal enhancement on breast MRI: impact on diagnostic performance.

DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD.

AJR Am J Roentgenol. 2012 Apr;198(4):W373-80. doi: 10.2214/AJR.10.6272.

PMID:
22451576
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk